A recent study published in the Journal of Ophthalmology has shown that consumption of a dairy drink containing lutein-, zeaxanthin- and DHA-enriched egg yolk significantly improves macular pigment optical density, visual acuity and plasma lutein concentration in healthy adult participants with regular signs of aging in the eyes, so called drusen and/or retinal pigment epithelial abnormalities.

“This study further confirms that MacuView has a profound effect on eye health,” said Jos Nelissen, CEO of Newtricious. “We’re pleased these results demonstrate that MacuView improves macular pigment optical density and sharpness of vision contributing to healthy vision.”

The study was a one-year, randomized, double-blind, placebo-controlled intervention trial conducted in adult subjects with ocular drusen and/or retinal pigment abnormalities. The yearlong trial included 101 subjects, 52 in the MacuView group and 49 subjects in the control group.

Key results showed that participants consuming the MacuView drink had the following improvements:

• An improvement in sharpness of vision, compared to decline in the control group.
• A 15.6% improvement from baseline in Macular Pigment Optical Density.
•  A 94% increase in plasma lutein concentrations.

Dark adaptation rate showed a tendency to increase in the intervention group and a decrease in the control group.

MacuView was developed by Newtricious for improvement and maintenance of healthy vision and to inhibit the progression of impaired sight such as Macular Degeneration, the leading cause of blindness in the U.S. The product is based on a patented formulation of egg yolk and dairy, and contains natural ingredients that includes lutein, zeaxanthin and DHA (omega-3); and all other vitamins and minerals that naturally occur in egg-yolk. MacuView has been studied in four clinical studies that have included over 400 individuals. A fifth multi-center study in renowned KOL centers in the USA, Germany, UK and the Netherlands is almost completed.

Besides eye health, the product is in an ongoing clinical study tested on cognition with results expected in second quarter of 2016.

For more information: www.newtricious.nl/en